International Assets Investment Management LLC Acquires Shares of 34,414 Grifols, S.A. (NASDAQ:GRFS)

International Assets Investment Management LLC acquired a new stake in Grifols, S.A. (NASDAQ:GRFS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 34,414 shares of the biotechnology company’s stock, valued at approximately $398,000.

A number of other hedge funds have also recently modified their holdings of the stock. Raymond James & Associates purchased a new stake in Grifols in the 3rd quarter worth approximately $254,000. Hennion & Walsh Asset Management Inc. boosted its holdings in Grifols by 6.5% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 178,413 shares of the biotechnology company’s stock worth $1,631,000 after buying an additional 10,954 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Grifols by 106.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,132 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,618 shares during the period. Syon Capital LLC acquired a new position in shares of Grifols in the third quarter worth about $250,000. Finally, NBC Securities Inc. acquired a new position in shares of Grifols in the third quarter worth about $259,000.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft lowered Grifols from a “hold” rating to a “sell” rating in a research note on Tuesday, March 12th.

Grifols Trading Up 1.8 %

Grifols stock opened at $6.38 on Friday. The company’s fifty day moving average price is $6.92 and its 200 day moving average price is $8.32. The company has a debt-to-equity ratio of 1.24, a current ratio of 2.83 and a quick ratio of 1.32. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $12.15.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.